← Back to headlines
AstraZeneca Shares Slump Amid Rumors of $400 Billion Bristol Myers Squibb Merger
AstraZeneca's stock fell significantly following market rumors of a potential $400 billion merger with Bristol Myers Squibb. Investors and analysts expressed skepticism about the strategic logic and potential benefits of such a large-scale pharmaceutical tie-up.
3 Aug, 16:14 — 4 Aug, 04:00
The Story
Analyzing sources…
Source Diversity
Source Diversity
Excellent (79/100)7 sources33/33
Spectrum spread— 4/5 buckets covered25/33
Far L1
Far Left (1)
The Independent
Left1
Left (1)
Yahoo
Center2
Center (2)
FTbloomberg
Right3
Right (3)
fazsvenska-dagbladetle-figaro
Far R
Geographic diversity— 5 regions21/34
UK2US2Germany1Sweden1France1
Sources
Showing 4 of 7 sources
bloombergHigh29d ago
AstraZeneca Investors See Little Logic in Bristol Tie-Up
AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. (Source: Bloomberg)
Read full article →FTVery High28d ago
The $400bn megadeal brewing in big pharma
AstraZeneca’s talks with Bristol Myers Squibb could create the world’s fourth-largest drugmaker by market value
Read full article →The IndependentMostly Factual29d ago
Stocks mixed as AstraZeneca merger talk dents FTSE 100
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
By Jeremy Cutler
Read full article →YahooMostly Factual29d ago
Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”
Read full article →Coverage Timeline
First report: le-figaro · 3 Aug, 08:56|Full coverage: 7 · 19h|Window: 19h
Left-leaningCenterRight-leaning
